Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 2Mesothelioma, Malignant 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1MSI-H Colorectal Cancer 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Anus Neoplasms 1Advanced Refractory Solid Tumors 1

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2regorafenib 1envafolimab 1P7170 compound 1N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Refractory Solid Tumors × regorafenib × Other solid neoplasm × Clear all
NCT04200404 2022-05-06

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

CStone Pharmaceuticals

Phase 1/2 Completed
19 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡